Over the years, men have tried a lot of things to cope with diminished sex drive — rhinoceros horn included. While that strategy created a lot of risk for the rhinoceros, a recent study published in PLOS ONE
found that our modern pharmaceutical solutions are posing significant risks to the men.
The study, by William Finkle and colleagues, examined the frequency of adverse side effects stemming from testosterone therapy. It found an increased risk of heart attack in men younger than 65 with a history of heart disease and in older men even without a history of heart disease. The study results have garnered a lot of interest and even prompted the Food and Drug Administration (FDA) to review the safety of the therapy. The results and their ripple effects are getting a lot of attention in the press and for a number of good reasons.
First, testosterone therapy has been a rapidly growing phenomenon. Some of the growth is related to our aging population, but their manufacturers have also promoted these hormone supplements as a cure for low testosterone or
“low T” (code for diminished sex drive) — and that has been controversial. Sexual references tend to generate a fair amount of press, all other things equal.
Second, any drug marketed with direct-to-consumer advertising can expect more press because it is familiar to the public and the advertising itself generates controversy. Patients are more likely to request an advertised drug from their physician and that can influence prescribing decisions.
Finally, and perhaps most importantly, this study is getting a lot of attention because it is well done. This is an observational study that examined a large population — 55,593 men. All of these men had been prescribed testosterone treatments and 48,539 of them were younger than 65 years old.
The study was executed with great care and its results reflect the power of observational studies to advance our understanding of complex events, especially those that are rare. The authors analyzed medical and drug claims from our Truven Health MarketScan® Research databases, meaning they had access to the most robust Big Data healthcare claims source in the industry. It has been referenced in hundreds of peer-reviewed studies and this one is an interesting new addition to the literature.
Superior data is a necessary condition for a quality study. It may not be as sexy as a cure for “low-T,” but it is rewarding to know that we provide a quality foundation for research that is headline-worthy.
Senior Vice President, Custom Services